Trials / Completed
CompletedNCT00904787
Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies
A Phase 1 Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- CASI Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To define the maximum tolerated dose of oral daily ENMD 2076 in patients with relapsed or refractory hematological malignancies
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ENMD-2076 | capsule, dose escalation, taken orally, daily in 28 day cycles |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2010-12-01
- Completion
- 2011-05-01
- First posted
- 2009-05-20
- Last updated
- 2011-08-04
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT00904787. Inclusion in this directory is not an endorsement.